Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has announced his departure to seek external development opportunities, according to local media. His last day in the role will be January 14, 2025.
Career Highlights at Eli Lilly China
During his tenure at Eli Lilly China, Jiang Yifei has held several senior management positions, including marketing director for South Africa and sub-Saharan Africa, and vice president of the diabetes products business unit. Notably, in the field of diabetes, he has been instrumental in the successful launch and sustained growth of blockbuster products such as dulaglutide.
Contributions to Neuroscience
In the neuroscience division, Jiang Yifei has led a team that made significant progress in the field of neurodegenerative diseases, such as Alzheimer’s disease. His leadership has been pivotal in promoting the development and commercialization of multiple innovative drugs, advancing the company’s efforts in this critical area of research.
Significance of the Departure
Jiang Yifei’s departure marks a significant transition for Eli Lilly China’s neuroscience division. His contributions to the field have been substantial, and his move to seek new opportunities is expected to open new avenues for both personal and professional growth.-Fineline Info & Tech
